List view / Grid view
6 October 2016 | By CI Precision
Venezuela’s largest pharmaceutical manufacturer, Laboratorios Leti S.A.V. is using the Ci-DMS Weigh and Dispense module from CI Precision to dispense both raw and packing materials for their processing plant...
6 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Following review of the safety data, the DSMB authorised that the clinical trial proceed with enrolment and dose escalation for the second cohort...
6 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The Patent Trial and Appeal Board (PTAB) found that the patent was valid in light of the challenges put forward by the petitioner...
5 October 2016 | By Pall Life Sciences
Pall Life Sciences is pleased to announce the commercial launch of the Cadence BioSMB Process system single-use flow path, continuous multi-column chromatography system...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
RedHill Biopharma, will shortly commence a study evaluating yeliva (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), pending final...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Data demonstrated that Novacyt’s proprietary technology platform, NOVAprep, and Cepheid’s Xpert HPV test produced highly accurate results...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Nanobiotix, a late clinical-stage nanomedicine company, has appointed Dr Mihail Obrocea as the Head of US Clinical Development and Noel Kurdi as the Director of Investor Relations. In the US, Nanobiotix has filed a new drug application for NBTXR3, as a treatment for prostate cancer and plans to initiate a…
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The company expects to complete the submission of the new drug application (NDA) for vyxeos by early 2017, and will request a priority review...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Regeneron Pharmaceuticals and Sanofi’s two placebo-controlled Phase 3 trials, evaluating dupixent (dupilumab) in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), met their primary endpoints evaluating the extent and severity of the disease.
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
KA2237 is a dual-selective inhibitor of two PI3K isoforms, p110β and p110δ. Inhibiting these two isoforms combines an immunotherapeutic response...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Click the video to watch the results live from the Nobel Prize Announcements in Chemistry 2016!
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The study met its primary objective which was to determine if 1200mg/day of BC1054 lipid formulated ibuprofen was non-inferior to standard soft gel ibuprofen capsules...
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
This second alecensa breakthrough therapy designation granted is based on phase 3 J-ALEX study, treat ALK-positive non-small cell lung cancer...
4 October 2016 | By Wickham Laboratories
Join us for a free webinar on risks, regulations and determining the best method for your product, 3rd November, 3PM GMT...
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The aim of Novartis' plaque psoriasis treatment is clear skin and was achieved by 68.5% of patients at Year 1 and this high rate was maintained to Year 4...
